Friday morning last week, Novo Nordisk caught the stock market by surprise when the company released its first quarterly report for 2022 half a week before it was scheduled to be published.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Extra data boosts Lundbeck's agitation case
Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.
FDA confirms rejection of Y-mabs' cancer drug
The US Food and Drug Administration has officially rejected a Y-mabs cancer drug, after it was voted down by a sub-committee in October.
Top news from MedWatch this week
Miss anything?
Acquisitions to help Coloplast attain growth goal
Coloplast aims to grow by 10%, and chairman of the board Lars Rasmussen thinks this will be realized through multiple acquisitions.
FDA approves Ferring microbiotica-based treatment
Ferring Pharmaceuticals has received US approval for its stomach infection treatment.
Associate Director, Global Drug Safety and Pharmacovigilance Scientist 
Strategic advisor and negotiator with in-depth knowledge of the pharmaceutical market 
Principal Test Engineer 
QA Specialist 
Medical Manager Denmark & Norway 
New Product Introduction Manager Nordics 
Chief consultant for Dansk Erhvervs Health and life science 
Project Lead, Regulatory Affairs 
Head of Engineering 
Supply Chain Manager 
Project Director of CMC & Device, Zealand Pharma A/S / 1801 
Laboratory assistants for an exciting QC department